E. Voest

Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer.

E. Smit, P. Roepman, H. Gelderblom, 2022, European journal of cancer.

Abstract GS1-07: The genomic landscape of 501 metastatic breast cancer patients

S. Sleijfer, J. Martens, M. Smid, 2019, General Session Abstracts.

Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients.

S. Sleijfer, H. Gelderblom, A. Huitema, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics

E. Cuppen, P. Roepman, A. J. van den Broek, 2022, ESMO open.

Are tumours angiogenesis‐dependent?

E. Voest, H. Verheul, R. Schlingemann, 2004, The Journal of pathology.

Are anxiety and depressed mood related to physical symptom burden? A study in hospitalized advanced cancer patients

A. Graeff, J. de Haes, E. Voest, 2007, Palliative medicine.

Managing unsolicited findings in genomics: A qualitative interview study with cancer patients

A. May, R. Bijlsma, M. Ausems, 2018, Psycho-oncology.

Efficacy of high-dose alkylating chemotherapy in the adjuvant treatment of HER2/neu-negative primary breast cancer: update of the Dutch randomized trial

S. Rodenhuis, M. Nooij, E. Wall, 2005, Breast Cancer Research.

A Phase 1 Comparative Pharmacokinetic and Cardiac Safety Study of Two Intravenous Formulations of CO‐101 in Patients With Advanced Solid Tumors

J. Schellens, H. Rosing, J. Beijnen, 2013, Journal of clinical pharmacology.

Factors influencing catheter-related infections in the Dutch multicenter study on high-dose chemotherapy followed by peripheral SCT in high-risk breast cancer patients

S. Rodenhuis, H. Boezen, M. Nooij, 2008, Bone Marrow Transplantation.